BACKGROUND: Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemotherapy regimen. METHODS: Twenty-nine eligible patients with advanced urothelial carcinoma were treated with docetaxel at a dose of 40 mg/m(2) over 1 hour followed by gemcitabine, 800 mg/m(2), over 30 minutes, both intravenously (i.v.) on Days 1 and 8. Cycles were repeated every 21 days until disease progression or a maximum of 6 cycles. RESULTS: Five patients obtained an objective response for an overall response rate of 17% (90% confidence interval, 7-33%). One patient achieved a complete clinical response. The median overall survival of the group was 7.7 months. Toxicity was moderate with granulocytopenia, anorexia, and fatigue being the most commonly noted side effects. CONCLUSIONS: Gemcitabine and docetaxel is an active second-line combination in patients with advanced urothelial carcinoma. Responses in visceral, lymph node, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and anorexia was common. Thromboembolic symptoms were reported and are of concern. The combination of gemcitabine and docetaxel has the potential to palliate a subset of previously treated patients with an adequate performance status. Copyright 2003 American Cancer Society.
BACKGROUND:Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemotherapy regimen. METHODS: Twenty-nine eligible patients with advanced urothelial carcinoma were treated with docetaxel at a dose of 40 mg/m(2) over 1 hour followed by gemcitabine, 800 mg/m(2), over 30 minutes, both intravenously (i.v.) on Days 1 and 8. Cycles were repeated every 21 days until disease progression or a maximum of 6 cycles. RESULTS: Five patients obtained an objective response for an overall response rate of 17% (90% confidence interval, 7-33%). One patient achieved a complete clinical response. The median overall survival of the group was 7.7 months. Toxicity was moderate with granulocytopenia, anorexia, and fatigue being the most commonly noted side effects. CONCLUSIONS:Gemcitabine and docetaxel is an active second-line combination in patients with advanced urothelial carcinoma. Responses in visceral, lymph node, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and anorexia was common. Thromboembolic symptoms were reported and are of concern. The combination of gemcitabine and docetaxel has the potential to palliate a subset of previously treated patients with an adequate performance status. Copyright 2003 American Cancer Society.
Authors: Gonzalo Gomez-Abuin; Eric Winquist; Walter M Stadler; Greg Pond; Pamela Degendorfer; John Wright; Malcolm J Moore Journal: Invest New Drugs Date: 2006-09-16 Impact factor: 3.850
Authors: Thomas Powles; Jonathan E Rosenberg; Guru P Sonpavde; Yohann Loriot; Ignacio Durán; Jae-Lyun Lee; Nobuaki Matsubara; Christof Vulsteke; Daniel Castellano; Chunzhang Wu; Mary Campbell; Maria Matsangou; Daniel P Petrylak Journal: N Engl J Med Date: 2021-02-12 Impact factor: 91.245
Authors: Jung Hyun Lee; Sung Gu Kang; Seung Tae Kim; Seok Ho Kang; In Keun Choi; Young Je Park; Sang Chul Oh; Deuk Jae Sung; Jae Hong Seo; Jun Cheon; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Kyong Hwa Park Journal: Cancer Res Treat Date: 2014-04-22 Impact factor: 4.679